



## Gastric Cancer: From Pathophysiologic Mechanisms to Therapeutic Strategies

Guest Editors:

**Dr. Jiang-Jiang Qin**

Institute of Basic Medicine and  
Cancer, Chinese Academy of  
Sciences (CAS), Hangzhou, China

**Dr. Xiaoqing Guan**

Zhejiang Cancer Hospital,  
Hangzhou, China

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editors

Despite the substantial progress made in our understanding of the causes, pathogenesis, diagnosis, and treatment of gastric cancer in the past few decades, this disease remains one of the leading causes of cancer death. The identification and validation of new and effective biomarkers and drug targets are needed for patients with gastric cancer. Recently, cutting-edge omics technologies, such as spatiotemporal omics and single-cell omics, have emerged, changing cancer research and treatment. These tools could help make significant progress in exploring the tumor microenvironment, cancer cell evolution and interaction with immune and stromal cells, etc., and identifying more specific and promising biomarkers and targets for human cancer, including gastric cancer.

We invite authors to submit original research and review articles that focus on basic and translational research on gastric cancer with various new and powerful technologies. The goal is to stimulate research and clinical interest in developing strategies for the prediction, prevention, diagnosis, and treatment of gastric cancer to finally improve the treatment outcomes in patients with this malignant disease.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)